Molecular Characterization of ESBL-producing uropathogenic Escherichia coli From Pregnant Women: Resistance Genes, Integrons, and Virulence Profiles
Abstract
Urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli pose a growing treatment challenge during pregnancy. In this cross-sectional study of 280 E. coli isolates from pregnant women at a tertiary center in Kayseri, Türkiye (April 2022-April 2023), we performed antimicrobial susceptibility testing; PCR for resistance genes (blaCTX-M1, blaCTX-M2, blaTEM, blaSHV, and seven carbapenemase genes), class 1/2 integrons, and six virulence genes. We assessed genetic relatedness among the isolates using restriction endonuclease analysis-pulsed-field gel electrophoresis (REA-PFGE). ESBL production was detected in 53/280 isolates (18.9%). ESBL-positive isolates showed significantly higher symptomatic presentation (64.2% vs. 26.0%; p < 0.001; OR 5.10, 95% CI: 2.73-9.54), higher multidrug resistance (81.1% vs. 12.3%), and greater carriage of virulence genes (67.9%). The predominant ESBL gene was blaCTX-M1 (54.7%), and class 1 integrons were detected in 37.7% of producers. Aerobactin and S-fimbriae were each found in 57.1% of pyelonephritis cases (n = 7), though this subgroup was too small for definitive conclusions. No carbapenem resistance was detected. REA-PFGE revealed 50 distinct pulsotypes among 52 isolates, suggesting polyclonal dissemination. Carbapenems, nitrofurantoin, and fosfomycin retained efficacy, supporting their continued use for empirical therapy in this setting.
© 2026 Yasemin AY Altintop, Nebahat Aydogan Ejder, Huseyin Aksoy, Aysegul Copur Cicek, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.